Rua Accelerates Export Strategy, Ceases Manufacturing
Rua Bioscience announces the export-led company will cease local GMP manufacturing and accelerate its global brand strategy, building its international product pipeline while developing valuable points of difference in the areas of genetic discovery and novel product development. Working with manufacturing partners, Rua expects New Zealand patients will ultimately benefit from a wider range of affordable medicines.
Rua Releases Market Insights 2023
Rua Bioscience has released its Market Insights for 2023.
The update is designed to share information about the challenges and opportunities presented by emerging high-value medicinal cannabis markets.
Rua Releases Half-Year Result – Results as expected, with German launch imminent
The Group reported a net profit after tax of $718,703 for the period ending 31 December 2022. Excluding fair value gain on contingent consideration of $4,100,932, the Group incurred an operating loss of $3,382,229.
The results are in line with expectations as the company established its product and revenue pipelines and further positioned itself to compete globally.
Rua Signs Supply Agreement, Targets Poland and Czechia
Rua Bioscience today announced it has signed a five-year master supply agreement with Motagon to supply medicinal cannabis products to Central and Eastern European countries. Critically, the agreement gives Rua access to the emerging medicinal cannabis markets of Czechia and Poland.
Update on the Impact of Cyclone Gabrielle
Rua Bioscience provides the following update on its operations in the wake of the regional disruptions caused by Cyclone Gabrielle.
Rua Announces Appointment of New CEO and Chair
Rua Bioscience has appointed Paul Naske as Chief Executive Officer. Interim Managing Director, Anna Stove, will return to Chair the Rua Board as Trevor Burt announces his retirement.
Rua Opens 2022 He Ara Atawhai – Undergraduate and Postgraduate Scholarships
Rua is now inviting specific East Coast kura to nominate students for our undergraduate scholarships as well as inviting all postgraduate students to apply for our postgraduate scholarships.
Rua Bioscience Confirms First International Order
Rua Bioscience Limited (NZX: RUA) formally announced today that it has received its first order via its German distributor Nimbus Health, marking a significant commercial milestone for the export-focused company.
Significant Headway Made with Trans-Tasman Medicinal Cannabis Partnership
Rua Bioscience’s cultivation partnership with Australian-based Cann Group is making significant headway; the two companies achieving key milestones this week.
Rua Releases Annual Results for the 12 months ended 30 June 2022
Director, Martin Smith, to Retire. AGM Date Set.
The Board of Directors of Rua Bioscience Limited advises that Mr Martin Smith has decided to retire as an Independent Non-Executive Director. Martin’s retirement will be effective at the conclusion of the 2022 Annual General Meeting scheduled for October 12, 2022.
Rua signs five-year agreement with European Medicinal Cannabis Distributor Motagon
Rua Bioscience has signed an agreement with European Medicinal Cannabis Distributor, Motagon to become its preferred Australia/NZ supplier of medicinal cannabis products.
Rua Bioscience CEO Rob Mitchell to retire - Anna Stove appointed Managing Director
Rua Bioscience Chief Executive Officer Rob Mitchell has advised the Board of his intention to retire from his role effective 1 September 2022.
Rua Chair Trevor Burt said that Rob Mitchell has built on the company’s solid foundations, leading Rua through significant milestones and developing new strategic partnerships.
Announcement of Director Appointment
The Chair of Rua Bioscience, Mr Trevor Burt, and the Rua Board are delighted to announce the appointment of Teresa Ciprian as an Independent Non-Executive Director, effective 1 August 2022.
Rua receives narcotic license through Nimbus Health for distribution and marketing of our first product for Germany
Rua Bioscience Limited announced today that it has received its narcotic license through Nimbus Health GmbH for distribution and marketing of its first product for the German medicinal cannabis market – a move understood to make Rua the first medicinal cannabis company from New Zealand to take such a step.
He Ara Ahumahi - Seeking the next generation of East Coast scientists, researchers, growers, communicators, and entrepreneurs
Rua Bioscience has just announced its inaugural Internship programme and is seeking two people to join its 30-strong team with both a winter and summer internship.
Rua launches our first medicine in New Zealand
Rua Bioscience, has today launched our first medicine, marking a significant milestone for New Zealand patients, prescribers and the medicinal cannabis industry.
Rua Half-Year Result – Constructive Period with First Product, First Revenue Imminent
Rua Half-Year Result – Constructive Period with First Product, First Revenue Imminent. Rua Bioscience Limited (NZX: RUA) has today announced its financial results for the six months to 31 December 2021.
The loss after tax for the six months to 31 December 2021 was $2.46m, with total cash and investments on hand at the end of the period of $12.29m.
Pharmaceutical Giant Acquires German Distributor Nimbus Health
Rua Bioscience is pleased to share the news that multi-national pharmaceutical company Dr Reddy's Laboratories Ltd today announced it has entered into a definitive agreement to acquire Nimbus Health. Rua Bioscience was the first New Zealand company to announce a binding export agreement with the reputable distributor in Germany and is Nimbus Health's exclusive New Zealand supplier of medicinal cannabis products.
Rua’s Australian Supplier, Cann Group, Receives GMP Certification for Southern Facility
Rua Bioscience is pleased to share that Cann Group has been granted a GMP licence to manufacture therapeutic goods for its Southern facility (Southern GMP Licence) by Australia’s Therapeutic Goods Administration (TGA).